GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

TBA-7371   Click here for help

GtoPdb Ligand ID: 13133

Synonyms: AZ-7371 | compound 1 [PMID:24957839] | TBA7371
Compound class: Synthetic organic
Comment: TBA-7371 was identified in a lead optimization study of a series of 1,4-azaindoles, a novel class of antibacterial compounds [1-3]. It has potent antimycobacterial activity and is under clinical evaluation as a treatment for tuberculosis (TB). TBA-7371 is a non-covalent inhibitor of decaprenylphosphoryl-beta-D-ribose oxidase (DprE1), an essential mycobacterial cell wall biosynthesis enzyme [1].

TBA-7371 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 98.88
Molecular weight 355.39
XLogP -0.61
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1=CN=C2C(=CN(CC3=NC=NC(=C3C)OC)C2=C1)C(=O)NCCO
Isomeric SMILES CC1=CC2=C(C(=CN2CC3=C(C(=NC=N3)OC)C)C(=O)NCCO)N=C1
InChI InChI=1S/C18H21N5O3/c1-11-6-15-16(20-7-11)13(17(25)19-4-5-24)8-23(15)9-14-12(2)18(26-3)22-10-21-14/h6-8,10,24H,4-5,9H2,1-3H3,(H,19,25)
InChI Key VDRYGTNDKXIPSK-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
TBA-7371 has completed a Phase 2 trial to evaluate safety, pharmacokinetics, and early bactericidal activity (EBA) in adult participants with rifampicin-sensitive pulmonary tuberculosis (NCT04176250).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03199339 A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371 Phase 1 Interventional Global Alliance for TB Drug Development
NCT04176250 Early Bactericidal Activity of TBA-7371 in Pulmonary Tuberculosis Phase 2 Interventional Bill & Melinda Gates Medical Research Institute